Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
SpecificiT Pharma logo — Pioneering personalized cancer therapies with a novel approa...

SpecificiT Pharma

Pioneering personalized cancer therapies with a novel approach using Minor Histocompatibility Antigens to target hematological cancers.

Founded 2016 0-1 employees Seed Biotechnology, Health Care +1

General Information

Company Name SpecificiT Pharma
Founded Year 2016
Employees 0-1
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with SpecificiT Pharma. To contact SpecificiT Pharma, visit specificitpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SpecificiT Pharma compare?

A PDF of SpecificiT Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SpecificiT Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SpecificiT Pharma

SpecificiT Pharma is a pioneering biopharmaceutical company founded in 2016 with a focus on creating innovative personalized cancer immunotherapies. The company's mission is to target hematological cancers using a novel approach that involves the utilization of Minor Histocompatibility Antigens (MiHAs), thereby enabling the donor T-cells to be safely directed towards eradicating cancer cells in patients. This distinctive method provides a valuable alternative for addressing hematological cancers, which are currently not effectively targeted by chimeric antigen receptor modified T cells (CAR-T) therapies. The last investment round for SpecificiT Pharma took place on 11 September 2017, where the company secured seed funding from notable investors including Amorchem, Sanderling Ventures, and Accel-Rx Health Sciences Accelerator. This financial backing signifies the confidence and support of key players in the biotechnology and pharmaceutical industries for the company's pioneering approach to cancer treatment. With its focus on biotechnology, health care, and the pharmaceutical sector, SpecificiT Pharma is positioned to make significant advancements in the field of personalized cancer therapies, addressing an unmet need in the treatment of hematological cancers. The company's dedication to innovation and novel approaches in cancer immunotherapy makes it a compelling opportunity for investors looking to support groundbreaking advancements in the healthcare industry.

Business keywords: Personalized medicine, Immunotherapy, Cancer treatment, Cell therapy, Biopharmaceuticals, Innovative therapies, Hematological cancers, CAR-T therapy, MiHAs, Oncology, Minor Histocompatibility Antigens, T-cell therapy

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 3
Amorchem Sanderling Ventures
Amorchem, Sanderling Ventures +1
11 Sep 2017

SpecificiT Pharma Alternatives & Competitors

View All Alternatives
SpecificiT Pharma vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
SpecificiT Pharma vs
ONK Therapeutics
ONK Therapeutics Ireland

Pioneering optimally engineered NK cell therapies to cure patients with cancer.

Series A
20 employees
Biotechnology, Health Care
SpecificiT Pharma vs
Leucid Bio
Leucid Bio United Kingdom

Thinking laterally about CAR-T. Develops Autologous and Allogeneic cell and gene Therapies for hard...

Series A
23 employees
Biotechnology, Health Care
View all alternatives

FAQ About SpecificiT Pharma

Pioneering personalized cancer therapies with a novel approach using Minor Histocompatibility Antigens to target hematological cancers.
SpecificiT Pharma was founded in 2016.
SpecificiT Pharma operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Personalized medicine, Immunotherapy, Cancer treatment and Cell therapy.
SpecificiT Pharma has approximately 0-1 employees.
SpecificiT Pharma has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to SpecificiT Pharma include Prescient Therapeutics, ONK Therapeutics, Leucid Bio, Autolus Therapeutics, ImmuneBridge. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SpecificiT Pharma and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SpecificiT Pharma, https://www.bouncewatch.com/company/specificit-pharma, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout